Skip to main content
Top
Published in: Molecular Diagnosis & Therapy 2/2016

01-04-2016 | Original Research Article

Structural and Functional Insights on an Uncharacterized Aγ-Globin-Gene Polymorphism Present in Four β0-Thalassemia Families with High Fetal Hemoglobin Levels

Authors: Nicoletta Bianchi, Lucia Carmela Cosenza, Ilaria Lampronti, Alessia Finotti, Giulia Breveglieri, Cristina Zuccato, Enrica Fabbri, Giovanni Marzaro, Adriana Chilin, Gioia De Angelis, Monica Borgatti, Cristiano Gallucci, Cecilia Alfieri, Michela Ribersani, Antonella Isgrò, Marco Marziali, Javid Gaziev, Aldo Morrone, Pietro Sodani, Guido Lucarelli, Roberto Gambari, Katia Paciaroni

Published in: Molecular Diagnosis & Therapy | Issue 2/2016

Login to get access

Abstract

Introduction

Several DNA polymorphisms have been associated with high production of fetal hemoglobin (HbF), although the molecular basis is not completely understood. In order to identify and characterize novel HbF-associated elements, we focused on five probands and their four families (from Egypt, Iraq and Iran) with thalassemia major (either β0-IVSII-1 or β0-IVSI-1) and unusual HbF elevation (>98 %), congenital or acquired after rejection of bone marrow transplantation, suggesting an anticipated favorable genetic background to high HbF expression.

Methods

Patient recruitment, genomic DNA sequencing, western blotting, electrophoretic mobility shift assays, surface plasmon resonance (SPR) biospecific interaction analysis, bioinformatics analyses based on docking experiments.

Results

A polymorphism of the Aγ-globin gene is here studied in four families with β0-thalassemia (β0-IVSII-1 and β0-IVSI-1) and expressing unusual high HbF levels, congenital or acquired after rejection of bone marrow transplantation. This (G→A) polymorphism is present at position +25 of the Aγ-globin genes, corresponding to a 5′-UTR region of the Aγ-globin mRNA and, when present, is physically linked in chromosomes 11 of all the familiar members studied to the XmnI polymorphism and to the β0-thalassemia mutations. The region corresponding to the +25(G→A) polymorphism of the Aγ-globin gene belongs to a sequence recognized by DNA-binding protein complexes, including LYAR (Ly-1 antibody reactive clone), a zinc-finger transcription factor previously proposed to be involved in down-regulation of the expression of γ-globin genes in erythroid cells.

Conclusion

We found a novel polymorphism of the Aγ-globin gene in four families with β0-thalassemia and high levels of HbF expression. Additionally, we report evidence suggesting that the Aγ-globin gene +25(G→A) polymorphism decreases the efficiency of the interaction between this sequence and specific DNA binding protein complexes.
Appendix
Available only for authorised users
Literature
2.
go back to reference Giardine B, Borg J, Viennas E, Pavlidis C, Moradkhani K, Joly P, et al. Updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic Acids Res. 2014;42 (Database issue):D1063–D1069. doi: 10.1093/nar/gkt911. Giardine B, Borg J, Viennas E, Pavlidis C, Moradkhani K, Joly P, et al. Updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic Acids Res. 2014;42 (Database issue):D1063–D1069. doi: 10.​1093/​nar/​gkt911.
3.
4.
go back to reference Weatherall DJ. Pathophysiology of thalassaemia. Bailliere’s Clin Haematol. 1998;11:127–46.CrossRef Weatherall DJ. Pathophysiology of thalassaemia. Bailliere’s Clin Haematol. 1998;11:127–46.CrossRef
5.
go back to reference Weatherall DJ. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet. 2001;2:245–55.CrossRefPubMed Weatherall DJ. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet. 2001;2:245–55.CrossRefPubMed
9.
go back to reference Fibach E, Bianchi N, Borgatti M, Zuccato C, Finotti A, Lampronti I, et al. Effects of rapamycin on accumulation of alpha-, beta- and gamma-globin mRNAs in erythroid precursor cells from beta-thalassaemia patients. Eur J Haematol. 2006;77:437–41.CrossRefPubMed Fibach E, Bianchi N, Borgatti M, Zuccato C, Finotti A, Lampronti I, et al. Effects of rapamycin on accumulation of alpha-, beta- and gamma-globin mRNAs in erythroid precursor cells from beta-thalassaemia patients. Eur J Haematol. 2006;77:437–41.CrossRefPubMed
10.
go back to reference Fibach E, Prus E, Bianchi N, Zuccato C, Breveglieri G, Salvatori F, et al. Resveratrol: antioxidant activity and induction of fetal hemoglobin in erythroid cells from normal donors and β-thalassemia patients. Int J Mol Med. 2012;29:974–82. doi:10.3892/ijmm.2012.928.PubMed Fibach E, Prus E, Bianchi N, Zuccato C, Breveglieri G, Salvatori F, et al. Resveratrol: antioxidant activity and induction of fetal hemoglobin in erythroid cells from normal donors and β-thalassemia patients. Int J Mol Med. 2012;29:974–82. doi:10.​3892/​ijmm.​2012.​928.PubMed
13.
go back to reference Gambari R, Fibach E. Medicinal chemistry of fetal hemoglobin inducers for treatment of beta-thalassemia. Curr Med Chem. 2007;14:199–212.CrossRefPubMed Gambari R, Fibach E. Medicinal chemistry of fetal hemoglobin inducers for treatment of beta-thalassemia. Curr Med Chem. 2007;14:199–212.CrossRefPubMed
16.
18.
21.
go back to reference Jiang J, Best S, Menzel S, Silver N, Lai MI, Surdulescu GL, et al. cMYB is involved in the regulation of fetal hemoglobin production in adults. Blood. 2006;108:1077–83.CrossRefPubMed Jiang J, Best S, Menzel S, Silver N, Lai MI, Surdulescu GL, et al. cMYB is involved in the regulation of fetal hemoglobin production in adults. Blood. 2006;108:1077–83.CrossRefPubMed
22.
24.
25.
go back to reference Paciaroni K, Gallucci C, De Angelis G, Alfieri C, Roveda A, Lucarelli G. Sustained and full fetal hemoglobin production after failure of bone marrow transplant in a patient homozygous for beta 0-thalassemia: a clinical remission despite genetic disease and transplant rejection. Am J Hematol. 2009;84:372–3. doi:10.1002/ajh.21392.CrossRefPubMed Paciaroni K, Gallucci C, De Angelis G, Alfieri C, Roveda A, Lucarelli G. Sustained and full fetal hemoglobin production after failure of bone marrow transplant in a patient homozygous for beta 0-thalassemia: a clinical remission despite genetic disease and transplant rejection. Am J Hematol. 2009;84:372–3. doi:10.​1002/​ajh.​21392.CrossRefPubMed
27.
go back to reference Paciaroni K, Lucarelli G, Martelli F, Migliaccio AR, von Lindern M, Borg J, Gillemans N, van Dijk TB, Philipsen S. Transfusion-independent β(0)-thalassemia after bone marrow transplantation failure: proposed involvement of high parental HbF and an epigenetic mechanism. Am J Blood Res. 2014;4:27–32.PubMedPubMedCentral Paciaroni K, Lucarelli G, Martelli F, Migliaccio AR, von Lindern M, Borg J, Gillemans N, van Dijk TB, Philipsen S. Transfusion-independent β(0)-thalassemia after bone marrow transplantation failure: proposed involvement of high parental HbF and an epigenetic mechanism. Am J Blood Res. 2014;4:27–32.PubMedPubMedCentral
28.
go back to reference Fibach E, Bianchi N, Borgatti M, Prus E, Gambari R. Mithramycin induces fetal hemoglobin production in normal and thalassemic human erythroid precursor cells. Blood. 2003;102:1276–81.CrossRefPubMed Fibach E, Bianchi N, Borgatti M, Prus E, Gambari R. Mithramycin induces fetal hemoglobin production in normal and thalassemic human erythroid precursor cells. Blood. 2003;102:1276–81.CrossRefPubMed
29.
go back to reference Lampronti I, Bianchi N, Zuccato C, Dall’acqua F, Vedaldi D, Viola G, et al. Increase in gamma-globin mRNA content in human erythroid cells treated with angelicin analogs. Int J Hematol. 2009;90:318–27. doi:10.1007/s12185-009-0422-2.CrossRefPubMed Lampronti I, Bianchi N, Zuccato C, Dall’acqua F, Vedaldi D, Viola G, et al. Increase in gamma-globin mRNA content in human erythroid cells treated with angelicin analogs. Int J Hematol. 2009;90:318–27. doi:10.​1007/​s12185-009-0422-2.CrossRefPubMed
30.
go back to reference Lozzio CB, Lozzio BB, Machado EA, Fuhr JE, Lair SV, Bamberger EG. Effects of sodium butyrate on human chronic myelogenous leukaemia cell line K562. Nature. 1979;281:709–10.CrossRefPubMed Lozzio CB, Lozzio BB, Machado EA, Fuhr JE, Lair SV, Bamberger EG. Effects of sodium butyrate on human chronic myelogenous leukaemia cell line K562. Nature. 1979;281:709–10.CrossRefPubMed
31.
go back to reference Bianchi N, Finotti A, Ferracin M, Zuccato C, Breveglieri G, Brognara E, et al. Increase of microRNA-210, decrease of raptor gene expression and alteration of mammalian target of rapamycin regulated proteins following mithramycin treatment of human erythroid cells. PLoS One. 2015;10:1–33. doi:10.1371/journal.pone.0121567. Bianchi N, Finotti A, Ferracin M, Zuccato C, Breveglieri G, Brognara E, et al. Increase of microRNA-210, decrease of raptor gene expression and alteration of mammalian target of rapamycin regulated proteins following mithramycin treatment of human erythroid cells. PLoS One. 2015;10:1–33. doi:10.​1371/​journal.​pone.​0121567.
34.
go back to reference Borgatti M, Lampronti I, Romanelli A, Pedone C, Saviano M, Bianchi N, et al. Transcription factor decoy molecules based on a peptide nucleic acid (PNA)-DNA chimera mimicking Sp1 binding sites. J Biol Chem. 2002;278:7500–9.CrossRefPubMed Borgatti M, Lampronti I, Romanelli A, Pedone C, Saviano M, Bianchi N, et al. Transcription factor decoy molecules based on a peptide nucleic acid (PNA)-DNA chimera mimicking Sp1 binding sites. J Biol Chem. 2002;278:7500–9.CrossRefPubMed
35.
go back to reference Romanelli A, Pedone C, Saviano M, Bianchi N, Borgatti M, Mischiati C, et al. Molecular interactions with nuclear factor kappaB (NF-kappaB) transcription factors of a PNA-DNA chimera mimicking NF-kappaB binding sites. Eur J Biochem. 2001;268:6066–75.CrossRefPubMed Romanelli A, Pedone C, Saviano M, Bianchi N, Borgatti M, Mischiati C, et al. Molecular interactions with nuclear factor kappaB (NF-kappaB) transcription factors of a PNA-DNA chimera mimicking NF-kappaB binding sites. Eur J Biochem. 2001;268:6066–75.CrossRefPubMed
36.
go back to reference Finotti A, Bianchi N, Fabbri E, Borgatti M, Breveglieri G, Gasparello J, et al. Erythroid induction of K562 cells treated with mithramycin is associated with inhibition of raptor gene transcription and mammalian target of rapamycin complex 1 (mTORC1) functions. Pharmacol Res. 2015;91:57–68. doi:10.1016/j.phrs.2014.11.005.CrossRefPubMedPubMedCentral Finotti A, Bianchi N, Fabbri E, Borgatti M, Breveglieri G, Gasparello J, et al. Erythroid induction of K562 cells treated with mithramycin is associated with inhibition of raptor gene transcription and mammalian target of rapamycin complex 1 (mTORC1) functions. Pharmacol Res. 2015;91:57–68. doi:10.​1016/​j.​phrs.​2014.​11.​005.CrossRefPubMedPubMedCentral
37.
39.
go back to reference Li ZL, Abe H, Ueki K, Kumagai K, Araki R, Otsuki Y, et al. Identification of c-Jun as bcl-2 transcription factor in human uterine endometrium. J Histochem Cytochem. 2003;51:1601–9.CrossRefPubMed Li ZL, Abe H, Ueki K, Kumagai K, Araki R, Otsuki Y, et al. Identification of c-Jun as bcl-2 transcription factor in human uterine endometrium. J Histochem Cytochem. 2003;51:1601–9.CrossRefPubMed
40.
go back to reference Marzaro G, Guiotto A, Borgatti M, Finotti A, Gambari R, Breveglieri G, et al. Psoralen derivatives as inhibitors of NF-κB/DNA interaction: synthesis, molecular modeling, 3D-QSAR, and biological evaluation. J Med Chem. 2013;56:1830–42. doi:10.1021/jm3009647.CrossRefPubMed Marzaro G, Guiotto A, Borgatti M, Finotti A, Gambari R, Breveglieri G, et al. Psoralen derivatives as inhibitors of NF-κB/DNA interaction: synthesis, molecular modeling, 3D-QSAR, and biological evaluation. J Med Chem. 2013;56:1830–42. doi:10.​1021/​jm3009647.CrossRefPubMed
41.
go back to reference van Dijk M, Bonvin AM. 3D-DART: a DNA structure modeling server. Nucleic Acids Res. 2009;37(Web Server Issue):W235–W239. van Dijk M, Bonvin AM. 3D-DART: a DNA structure modeling server. Nucleic Acids Res. 2009;37(Web Server Issue):W235–W239.
42.
go back to reference Hess B, Kutzner C, van der Spoel D, Lindahl E. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput. 2008;4:435–47. doi:10.1021/ct700301q.CrossRefPubMed Hess B, Kutzner C, van der Spoel D, Lindahl E. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput. 2008;4:435–47. doi:10.​1021/​ct700301q.CrossRefPubMed
43.
go back to reference Dominguez C, Boelens R, Bonvin AM. HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. J Am Chem Soc. 2003;125:1731–7.CrossRefPubMed Dominguez C, Boelens R, Bonvin AM. HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. J Am Chem Soc. 2003;125:1731–7.CrossRefPubMed
45.
go back to reference DeLano WL. The PyMOL molecular graphics system. San Carlos: DeLano Scientific; 2002. DeLano WL. The PyMOL molecular graphics system. San Carlos: DeLano Scientific; 2002.
46.
go back to reference Dolinsky TJ, Nielsen JE, McCammon JA, Baker NA. PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res. 2004;32:W665–7.CrossRefPubMedPubMedCentral Dolinsky TJ, Nielsen JE, McCammon JA, Baker NA. PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res. 2004;32:W665–7.CrossRefPubMedPubMedCentral
48.
go back to reference Nguyen TK, Joly P, Bardel C, Moulsma M, Bonello-Palot N, Francina A. The XmnI (G)gamma polymorphism influences hemoglobin F synthesis contrary to BCL11A and HBS1L-MYB SNPs in a cohort of 57 beta-thalassemia intermedia patients. Blood Cel Mol Dis. 2010;45:124–7.CrossRef Nguyen TK, Joly P, Bardel C, Moulsma M, Bonello-Palot N, Francina A. The XmnI (G)gamma polymorphism influences hemoglobin F synthesis contrary to BCL11A and HBS1L-MYB SNPs in a cohort of 57 beta-thalassemia intermedia patients. Blood Cel Mol Dis. 2010;45:124–7.CrossRef
Metadata
Title
Structural and Functional Insights on an Uncharacterized Aγ-Globin-Gene Polymorphism Present in Four β0-Thalassemia Families with High Fetal Hemoglobin Levels
Authors
Nicoletta Bianchi
Lucia Carmela Cosenza
Ilaria Lampronti
Alessia Finotti
Giulia Breveglieri
Cristina Zuccato
Enrica Fabbri
Giovanni Marzaro
Adriana Chilin
Gioia De Angelis
Monica Borgatti
Cristiano Gallucci
Cecilia Alfieri
Michela Ribersani
Antonella Isgrò
Marco Marziali
Javid Gaziev
Aldo Morrone
Pietro Sodani
Guido Lucarelli
Roberto Gambari
Katia Paciaroni
Publication date
01-04-2016
Publisher
Springer International Publishing
Published in
Molecular Diagnosis & Therapy / Issue 2/2016
Print ISSN: 1177-1062
Electronic ISSN: 1179-2000
DOI
https://doi.org/10.1007/s40291-016-0187-2

Other articles of this Issue 2/2016

Molecular Diagnosis & Therapy 2/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine